MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$176,583K
Free Cash flow
-$54,466K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Share-based compensation expense
Accrued expenses and other curre...
Accounts payable
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Net loss
Operating lease liabilities
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-69,355
-26,087
-53,179
-53,852
Amortization of right-of-use assets
1,511
1,464
1,418
1,374
Depreciation of property and equipment
858
841
844
856
Accretion of investment premium
65
-
-
-
Share-based compensation expense
10,733
9,063
7,352
6,472
Accounts receivable
888
-1,276
-8,724
8,383
Prepaid expenses
-1,104
4,830
1,742
-47
Other assets
722
751
452
-4,847
Accounts payable
1,568
3,289
1,156
59
Accrued expenses and other current liabilities
5,199
-13,521
10,077
3,461
Deferred revenue
-1,385
-28,246
-5,968
2,392
Operating lease liabilities
-2,140
-2,051
-2,006
-1,939
Other non-current liabilities
-
-
0
-
Net cash used in operating activities
-53,582
-59,553
-33,776
-44,666
Purchases of property and equipment
884
438
-1
248
Purchases of marketable securities
122,570
-
-
-
Net cash used in investing activities
-123,454
-438
1
-248
Proceeds from the issuance of ordinary shares, net of offering costs
-
-
-
0
Proceeds from issuance of ordinary shares-December Two Thousand Twenty Five Offering
-
-
330,912
-
Proceeds from the issuance of pre-funded warrants, net of offering costs
-
-
-
0
Proceeds from issuance pre-funded warrants, net of offering costs-December Two Thousand Twenty Five Offering
-
-
46,938
-
Proceeds from issuance of ordinary shares pursuant to the at-the-market equity program, net of offering costs
0
0
52,063
30,212
Proceeds from the exercise of share options
330
1,934
9,782
2,041
Proceeds from the espp
0
593
0
439
Net cash provided by financing activities
330
2,527
439,695
32,692
Effect of foreign exchange rates on cash, cash equivalents, and restricted cash
123
-4
-60
-29
Net decrease in cash, cash equivalents, and restricted cash
-176,583
-57,468
405,860
-12,251
Cash, cash equivalents, and restricted cash, beginning of period
548,406
605,874
200,014
305,838
Cash, cash equivalents, and restricted cash, end of period
371,823
548,406
605,874
200,014
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from the
exercise of share options
$330K
(-89.16%↓ Y/Y)
Net cash provided by
financing activities
$330K
(-97.92%↓ Y/Y)
Effect of foreign
exchange rates on cash,...
$123K
(21.78%↑ Y/Y)
Net decrease in
cash, cash...
-$176,583K
(-88.71%↓ Y/Y)
Canceled cashflow
$453K
Share-based compensation
expense
$10,733K
(-3.73%↓ Y/Y)
Accrued expenses and
other current...
$5,199K
(164.54%↑ Y/Y)
Accounts payable
$1,568K
(188.29%↑ Y/Y)
Amortization of right-of-use
assets
$1,511K
(-42.33%↓ Y/Y)
Prepaid expenses
-$1,104K
(61.18%↑ Y/Y)
Depreciation of property and
equipment
$858K
(-50.69%↓ Y/Y)
Net cash used in
investing activities
-$123,454K
(-26111.04%↓ Y/Y)
Net cash used in
operating activities
-$53,582K
(50.87%↑ Y/Y)
Canceled cashflow
$20,973K
Purchases of marketable
securities
$122,570K
Purchases of property and
equipment
$884K
(87.69%↑ Y/Y)
Net loss
-$69,355K
(28.75%↑ Y/Y)
Operating lease
liabilities
-$2,140K
(42.05%↑ Y/Y)
Deferred revenue
-$1,385K
(91.48%↑ Y/Y)
Accounts receivable
$888K
(355.38%↑ Y/Y)
Other assets
$722K
(791.36%↑ Y/Y)
Accretion of investment
premium
$65K
Buy us a coffee
Wave Life Sciences Ltd. (WVE)
Wave Life Sciences Ltd. (WVE)